| 2024/07/18 08:00:41 | |
|---|---|
| Price | |
| 124.22 EUR | |
| Difference | 0.08% (0.10) |
General attributes
| ISIN | DK0062498333 |
| Symbol | NOVO B |
| Exchange | Hanover |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 410,869 EUR |
| Benchmark | OMX COPENHAGEN 20 |
Market data
| Bid (Bid size) | 123.38 EUR (500) |
| Ask (Ask size) | 123.42 EUR (500) |
| Open | 124.22 EUR |
| High | 124.22 EUR |
| Low | 124.22 EUR |
| Close (prev. day) | 124.12 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 1 |
| Last size | 0 |
Futures and Options
| Related Futures | 30 |
| Related Options | - |
PDF Downloads
| Company report: NOVO-NORDISK AS B |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/07/12 |
|
Global Equity Ratings |
|
| 2024/06/21 |
|
Global Equity Ratings |
|
| 2024/06/14 |
|
Global Equity Ratings |
|
| 2024/05/29 |
|
Global Equity Ratings |
|
| 2024/04/26 |
|
Global Equity Ratings |
|
| 2024/07/18 08:00:41 | |
|---|---|
| Price | |
| 124.22 EUR | |
| Difference | 0.08% (0.10) |
General attributes
| ISIN | DK0062498333 |
| Symbol | NOVO B |
| Exchange | Hanover |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 410,869 EUR |
| Benchmark | OMX COPENHAGEN 20 |
Market data
| Bid (Bid size) | 123.38 EUR (500) |
| Ask (Ask size) | 123.42 EUR (500) |
| Open | 124.22 EUR |
| High | 124.22 EUR |
| Low | 124.22 EUR |
| Close (prev. day) | 124.12 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 1 |
| Last size | 0 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | +26.85% | +72.63% | +235.78% |
| Perf (abs.) | +26.27 | +52.22 | +87.16 |
| Beta | 1.36 | 1.43 | 1.27 |
| Volatility | 30.27 | 33.38 | 32.15 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 128.88 EUR (82) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 131.90 EUR (46) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 123.03 EUR (54) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 104.86 EUR (64) |
| YTD High | date | 138.82 EUR (2024/06/26) |
| YTD Low | date | 93.00 EUR (2024/01/03) |
| 52 Weeks High | date | 138.82 EUR (2024/06/26) |
| 52 Weeks Low | date | 71.20 EUR (2023/07/18) |
All listings for NOVO-NORDISK AS B
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Xetra | 2024/07/18 | 09:17 | 123.66 EUR | 0.72 | 88 |
| Vienna Stock Exchange | 2024/07/18 | 09:05 | 124.04 EUR | 0.00 | 1 |
| Tradegate | 2024/07/18 | 09:19 | 123.40 EUR | 0.50 | 81 |
| Stuttgart | 2024/07/18 | 09:10 | 123.54 EUR | 0.03 | 4 |
| Nasdaq Copenhagen | 2024/07/18 | 09:20 | 920.70 DKK | 180.08 | 2,399 |
| Munich | 2024/07/18 | 08:05 | 124.22 EUR | 0.00 | 1 |
| London Stock Exchange European Trade Reporting | 2024/07/18 | 09:10 | 922.40 DKK | 0.19 | 14 |
| Hanover | 2024/07/18 | 08:00 | 124.22 EUR | 0.00 | 1 |
| Hamburg | 2024/07/18 | 08:02 | 124.26 EUR | 0.00 | 1 |
| Frankfurt | 2024/07/18 | 09:18 | 123.54 EUR | 0.21 | 9 |
| FINRA other OTC Issues | 2024/07/17 | 21:59 | 134.25 USD | 0.26 | 44 |
| Duesseldorf | 2024/07/18 | 08:12 | 124.00 EUR | 0.00 | 1 |
| Berlin | 2024/07/18 | 08:55 | 124.18 EUR | 0.00 | 2 |
Company Logo
Contact Details
| NOVO NORDISK A/S |
| - - |
| Novo Allé 1 - 2880 Bagsværd |
| Telefon: +45-44-44-88-88 |
| Fax: + |
| E-mail: - |
PDF Downloads
| Company report: NOVO-NORDISK AS B | |
Company Profile
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark. |
Members of Management Board
| Lars Fruergaard Jørgensen | Chairman of Managing Board |
| Camilla Sylvest | Member of Executive Committee |
| David Moore | Member of Executive Committee |
| Doug Langa | Member of Executive Committee |
| Henrik Wulff | Member of Executive Committee |
| Karsten Munk Knudsen | Member of Executive Committee |
| Ludovic Helfgott | Member of Executive Committee |
| Marcus Schindler | Member of Executive Committee |
| Martin Holst Lange | Member of Executive Committee |
| Maziar Mike Doustdar | Member of Executive Committee |
| Tania Sabroe | Member of Executive Committee |
Board of directors
| Helge Lund | Chairman of Supervisory Board |
| Martin MacKay | Member of Supervisory Board |
| Sylvie Grégoire | Member of Supervisory Board |
| Andreas Fibig | Member of Supervisory Board |
| Christina Law | Member of Supervisory Board |
| Elisabeth Christensen | Member of Supervisory Board |
| Henrik Poulsen | Member of Supervisory Board |
| Kasim Kutay | Member of Supervisory Board |
| Laurence Debroux | Member of Supervisory Board |
| Liselotte Hyveled | Member of Supervisory Board |
| Mette Bøjer Jensen | Member of Supervisory Board |
| Thomas Rantzau | Member of Supervisory Board |